The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...
Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...
Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not ...
Overall, mortality was lower, and lesions resolved faster than anticipated – regardless of whether participants received tecovirimat or placebo, according to the NIH. Tecovirimat was found to be ...
83% of participants on tecovirimat achieved clinical resolution, compared to 84% on placebo, which was not significantly different. Pain reduction was similar in both groups, with tecovirimat ...
Tecovirimat 200mg/vial; soln for IV infusion after dilution; contains hydroxypropyl-β-cyclodextrin. Store Tpoxx injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback